Imitation and innovation new biologics, biosimilars and biobetters
暂无分享,去创建一个
[1] J. Niosi. Biotechnology: a case of delayed international convergence? , 2014 .
[2] Eric Maskin,et al. Sequential Innovation, Patents, and Imitation , 2000 .
[3] C. Shapiro,et al. R&D Rivalry with Licensing or Imitation , 1987 .
[4] D. B. Montgomery,et al. First‐mover advantages , 1988 .
[5] F. G. Kilgour. The evolution of the book , 1998 .
[6] John P. Ulhøi,et al. Modes and orders of market entry: revisiting innovation and imitation strategies , 2012, Technol. Anal. Strateg. Manag..
[7] N. Hermes. The rise of 'the rest' : Challenges to the west from late-industrializing economies. , 2003 .
[8] Araújo,et al. An Evolutionary theory of economic change , 1983 .
[9] D. Eleanor Westney. Imitation and innovation : the transfer of Western organizational patterns to Meiji Japan , 1989 .
[10] Junying Huang,et al. Imitative innovation strategies , 2010 .
[11] K. Zhou. Innovation, imitation, and new product performance: The case of China , 2006 .
[12] D. B. Montgomery,et al. First-mover (dis)advantages: Retrospective and link with the resource-based view , 1998 .
[13] Esther Gal-Or,et al. First Mover Disadvantages with Private Information , 1987 .
[14] Roy Cerqueti,et al. On the coexistence of innovators and imitators , 2015 .
[15] George Basalla,et al. The Evolution of Technology: Selection (2): Social and Cultural Factors , 1989 .
[16] J. W. Hutchinson,et al. When business is a confidence game. , 2001, Harvard business review.
[17] Steve Little,et al. From Imitation to Innovation: The Evolution of R&D Capabilities and Learning Processes in the Indian Pharmaceutical Industry , 2007, Technol. Anal. Strateg. Manag..
[18] David L. Deeds,et al. Strategic alliances and the rate of new product development: An empirical study of entrepreneurial biotechnology firms , 1996 .
[19] J. Ang,et al. Catching Up to the Technology Frontier: The Dichotomy Between Innovation and Imitation , 2010 .
[20] F. Malerba,et al. The evolution of the pharmaceutical industry , 2015 .
[21] Edwin Mansfield,et al. How Rapidly Does New Industrial Technology Leak Out , 1985 .
[22] C. L. Ventola. Biosimilars: part 1: proposed regulatory criteria for FDA approval. , 2013, P & T : a peer-reviewed journal for formulary management.
[23] Bernard Haudeville. About Frugal Innovation , 2016 .
[24] Tymofiy Mylovanov,et al. First-mover disadvantage , 2005 .
[25] Gerhard Schewe,et al. Imitation as a strategic option for external acquisition of technology , 1996 .
[26] A. Ordanini,et al. The Many Moods of Inter-Organizational Imitation: A Critical Review , 2008 .
[27] Daniel A. Levinthal,et al. ABSORPTIVE CAPACITY: A NEW PERSPECTIVE ON LEARNING AND INNOVATION , 1990 .
[28] Kim B. Clark,et al. Architectural Innovation: The Reconfiguration of Existing Product Technologies and the Failure of , 1990 .
[29] J. Schumpeter. The Theory of Economic Development: An Inquiry into Profits, Capital, Credit, Interest, and the Business Cycle , 1934 .
[30] Cristiano Antonelli,et al. The economics of innovation: from the classical legacies to the economics of complexity , 2009 .
[31] J. DiMasi,et al. The cost of biopharmaceutical R&D: is biotech different? , 2007 .
[32] Alfred D. Chandler,et al. Shaping the Industrial Century: The Remarkable Story of the Evolution of the Modern Chemical and Pharmaceutical Industries , 2004 .
[33] W. Ashworth,et al. The Unbound Prometheus: Technological Change and Industrial Development in Western Europe from 1750 to the Present. , 1970 .
[34] Enrico Valdani,et al. Strategies of imitation: an insight , 2017 .
[35] Peter Sinclair. THE ECONOMICS OF IMITATION , 1990 .
[36] P. Bierly,et al. Generic knowledge strategies in the U.S. pharmaceutical industry , 1996 .
[37] Alex Coad,et al. Appropriate business strategy for leaders and laggards , 2011 .
[38] J. Benoît,et al. Innovation and Imitation in a Duopoly , 1985 .
[39] Radha Ramaswami Basu,et al. 7 – Frugal innovation , 2013 .
[40] Louis T. Wells. Third World multinationals , 1982 .
[41] W. Mitchell,et al. The effect of introducing important incremental innovations on market share and business survival , 1995 .
[42] Joachim M. Greuel. Assessing the Economics of Biogenerics , 2005 .
[43] Oliver Gassmann,et al. Models for open innovation in the pharmaceutical industry. , 2013, Drug discovery today.
[44] A. Nerkar,et al. Fail Often, Fail Big, and Fail Fast? Learning from Small Failures and R&D Performance in the Pharmaceutical Industry , 2015 .
[45] Jinyun Sun,et al. Emerging Economy Copycats: Capability, Environment, and Strategy , 2011 .
[46] B. Calvo,et al. The US approach to biosimilars: the long-awaited FDA approval pathway. , 2012, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.
[47] Ann Thayer. Biobetters May Be A Better Bet , 2014 .
[48] Katrin Baumgartner. Between Imitation And Innovation The Transfer And Hybridization Of Productive Models In The International Automobile Industry , 2016 .
[49] Keun Lee,et al. Technological Regimes, Catching-Up and Leapfrogging: Findings from the Korean Industries , 2001 .
[50] Petr Hanel,et al. The international diffusion of biotechnology: the arrival of developing countries , 2012 .
[51] R. Nelson. Why do firms differ, and how does it matter? , 1991 .
[52] S. Winter,et al. An evolutionary theory of economic change , 1983 .
[53] Pamela R. Haunschild,et al. Modes of Interorganizational Imitation: The Effects of Outcome Salience and Uncertainty , 1997 .
[54] M. Bolton,et al. Imitation versus innovation: Lessons to be learned from the Japanese , 1993 .
[55] Edwin Mansfield,et al. R&D and Innovation: Some Empirical Findings , 1984 .